Inovio Pharmaceuticals has announced the amending of an existing agreement with ApolloBio.    Based on the new agreement, ApolloBio will make an upfront payment of $23 million (an increase from the previously announced amount of $15 million), as well as potential future payments up to $20 million upon meeting certain milestones.  In addition, Inovio is entitled to receive double-digit tiered royalty payments on sales. The parties have also now agreed to terminate ApolloBio’s right to pur...